1. Home
  2. CNXC vs SVRA Comparison

CNXC vs SVRA Comparison

Compare CNXC & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concentrix Corporation

CNXC

Concentrix Corporation

HOLD

Current Price

$24.41

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Logo Savara Inc.

SVRA

Savara Inc.

HOLD

Current Price

$5.38

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNXC
SVRA
Founded
1991
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2020
2009

Fundamental Metrics

Financial Performance
Metric
CNXC
SVRA
Price
$24.41
$5.38
Analyst Decision
Strong Buy
Buy
Analyst Count
5
9
Target Price
$54.80
$7.33
AVG Volume (30 Days)
1.1M
1.6M
Earning Date
03-24-2026
05-13-2026
Dividend Yield
5.79%
N/A
EPS Growth
N/A
N/A
EPS
1.20
N/A
Revenue
$9,825,771,000.00
N/A
Revenue This Year
$5.29
N/A
Revenue Next Year
$2.49
$430.87
P/E Ratio
$20.73
N/A
Revenue Growth
2.15
N/A
52 Week Low
$19.12
$2.92
52 Week High
$57.88
$7.01

Technical Indicators

Market Signals
Indicator
CNXC
SVRA
Relative Strength Index (RSI) 48.42 43.31
Support Level $21.85 $5.28
Resistance Level $26.39 $5.43
Average True Range (ATR) 1.39 0.28
MACD -0.05 -0.02
Stochastic Oscillator 24.26 21.76

Price Performance

Historical Comparison
CNXC
SVRA

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

About SVRA Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Share on Social Networks: